ANTX

AN2 Therapeutics, Inc.

Pharmaceutical Preparations · SIC 2834CIK 1880438Held by 2 tracked managersEDGAR filings ↗10-K/10-Q ↗

SHARE:X LINKEDIN EMAIL

Revenue FY2025

—

Net Income FY2025

$(35.0M)

EPS (Basic, as reported)

$-1.16

Net Margin FY2025

—

ROE FY2025

-66.3%

Total Equity

$53.0M

Shares Out

38M

Business description

AN2 Therapeutics, Inc. — Pharmaceutical Preparations. Figures are as reported in each year's original 10-K via SEC EDGAR XBRL company facts (FY2021–FY2025; structured XBRL data begins around 2008). Market-price metrics are not part of EDGAR data.

Annual (fiscal years, as reported)USD millions

default rows · click any row to chart itNet income: (22) → (35)

Fiscal yearFY2021⚑FY2022⚑FY2023FY2024FY2025

Research & development(16)(29)(55)(40)(25)

General & administrative(5)(13)(15)(14)(13)

Total operating expenses(22)(42)(70)(57)(38)

Operating income(22)(42)(70)(57)(38)

Interest & investment income——553

Other income (expense), net00000

Income tax expense00000

Net income(22)(41)(65)(51)(35)

EPS — basic($10.64)($2.79)($2.74)($1.72)($1.16)

EPS — diluted($10.64)($2.79)($2.74)($1.72)($1.16)

Shares outstanding — basic (M)315243030

Shares outstanding — diluted (M)315243030

⚑ Weighted-average shares changed ×5.00 between FY2021 and FY2022 — likely a stock split. Per-share figures on either side are as reported and not adjusted.
⚑ Weighted-average shares changed ×1.60 between FY2022 and FY2023 — a large issuance or reduction. Per-share figures on either side are as reported and not adjusted.

Source: SEC EDGAR XBRL company facts — figures as reported in each period's original filing (structured data begins ~2008). EPS and other per-share figures are as reported and are not adjusted for later stock splits; a ⚑ marks a period where the reported share count changed by a large factor. Dollar figures in millions unless per-share. Line items a company never reports are omitted. Where a filer switched XBRL concepts, the successor concept is used and definitions can differ slightly (e.g. cash may include restricted cash; banks' revenue is net of interest expense; cost of revenue may exclude D&A; net income may be the amount available to common stockholders; debt issued/repaid may be net of issuance costs or include finance-lease obligations — each only where the original concept stopped being reported). Click a period header to open that period's source filing on EDGAR.